Scientific publications

In depth hub for scientific knowledge

Scientific publications

  • Biodistribution and dosimetry of [Lu-177]Lu‐SibuDAB in patients with metastatic castration‐resistant prostate cancer

     Philipp Ritt, René Fernández, Cristian Soza-Ried, Heinz Nicolai, Horacio Amaral, Korbinian Krieger, Ana Katrina Mapanao, Amanda Rotger, Konstantin Zhernosekov, Roger Schibli, Cristina Müller & Vasko Kramer

    Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve the tumour accumulation, new PSMA ligands were developed with an albumin-binding entity to enhance the blood circulation and, hence, tumour accumulation. In preclinical studies, [Lu-177]Lu-SibuDAB, a radiopharmaceutical with moderate albumin-binding properties, outperformed [177Lu]Lu-PSMA-617 and [Lu-177]Lu-PSMA-I&T. The aim of this study was to evaluate the dosimetry of [Lu-177]Lu-SibuDAB in patients diagnosed mCRPC.

  • Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT

     Grob, D., Privé, B.M., Muselaers, C.H.J. et al. Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT. EJNMMI Phys 11, 34 (2024).

    Bone marrow toxicity in advanced prostate cancer patients who receive [Lu-177]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [Lu-177]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference.

  • Internal dosimetry study of [Rb-82]Cl using a long axial field-of-view PET/CT

     Mercolli, L., Bregenzer, C., Diemling, M. et al. Internal dosimetry study of [82Rb]Cl using a long axial field-of-view PET/CT. Eur J Nucl Med Mol Imaging (2024).

    Our study suggests that the radiation dose associated with [Rb-82]Cl PET/CT can be assessed by means of dynamic LAFOV PET and that it is lower compared to literature values.

  • Anatomically guided reconstruction improves lesion quantitation and detectability in bone SPECT/CT

     Vuohijoki, H, Constable C, Sahlberg AO.

    Bone single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging suffers from poor spatial resolution, but the image quality can be improved during SPECT reconstruction by using anatomical information derived from CT imaging.

  • Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer.

     Arvola S, Seppänen M, Malaspina S, Mätzke S, Raiko J, Timonen KL, Ettala O, Jambor I, Anttinen M, Kuisma A, Löyttyniemi E, Boström PJ, Sohlberg A, Noponen T.

    The aim of this study was to compare reprojected bone SPECT/CT (RBS) against planar bone scintigraphy (BS) in the detection of bone metastases in breast and prostate cancer patients.

  • Total Tumor Volume on F18-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with Ac.225-PSMA-I&T

     Unterrainer, L.M.; Beyer, L.; Zacherl, M.J.; Gildehaus, F.J.; Todica, A.; Kunte, S.C.; Holzgreve, A.; Sheikh, G.T.; Herlemann, A.; Casuscelli, J.; Brendel, M.; Albert, N.L.; Wenter, V.; Schmidt-Hegemann, N.-S.; Kunz, W.G.; Cyran, C.C.; Ricke, J.; Stief, C.G.; Bartenstein, P.; Ilhan, H.; Unterrainer, M.

    PSMA-based alpha therapy using 225Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therapy outcomes and plays an increasing role in mCRPC patients. Hence, we aimed to assess TTV and its changes during 225Ac-PSMA-I&T RLT.

  • Comparing calculated and experimental activity and dose values obtained from image-based quantification of Y-90 SPECT/CT Data.

     Lotter K, Diemling M, Sohlberg A, Wiedner H, Haug A, Maringer FJ.

    Selective internal radiation therapy (SIRT) is a treatment for various kinds of liver tumours by injecting Y-90 bearing microspheres into the liver vessels. To perform meaningful post-treatment dosimetry, quantitative imaging is performed.

  • Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients.

     Mittlmeier LM, Brendel M, Beyer L, et al.

    Delineation of PSMA-positive tumor volume on PET using PSMA-ligands is of highest clinical interest as changes of PSMA-PET/CT-derived whole tumor volume (WTV) have shown to correlate with treatment response in metastatic prostate cancer patients.

  • Quantitative bone SPECT/CT reconstruction utilizing anatomical information

     Tuija S. Kangasmaa et al.

    Bone SPECT/CT has been shown to offer superior sensitivity and specificity compared to conventional whole-body planar scanning. Furthermore, bone SPECT/CT allows quantitative imaging, which is challenging with planar methods …